Sat, Apr 19, 2014, 1:29 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Pernix Therapeutics Holdings, Inc. Message Board

yyyprionyyy 64 posts  |  Last Activity: Apr 11, 2014 8:52 AM Member since: Jan 13, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • yyyprionyyy yyyprionyyy Apr 11, 2014 8:52 AM Flag

    PV-10
    Liver Metastasis
      
    •    Phase 1 protocol expansion September 2012 through 2013 into 2014
    •    Orphan drug status April 2011
    •    Phase 1 patient accrual and treatment completed January 2011
    •    Phase 1 study initiated October 2009

    PV-10
    Mechanism of Action
      

      
    Moffitt Cancer Center initiates Phase 1 feasibility study to detect immune cell infiltration into melanomas treated by PV-10 in January 2013 into 2014
    In addition to clinical trials, patients enrolled in the compassionate use or expanded access program for PV-10 are also receiving PV-10 treatments.
    -------------
    In addition to clinical trials, patients enrolled in the compassionate use or expanded access program for PV-10 are also receiving PV-10 treatments.
    -----------
    In addition to clinical trials, patients enrolled in the compassionate use or expanded access program for PV-10 are also receiving PV-10 treatments.

    How many more in the patients enrolled in the compassionate use ????????? Anyone???

  • We focus on developing our prescription drug candidates PV-10 and PH-10. We are developing PV-10 for treatment of several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer. We are developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema. We believe that our prescription drug candidates will be safer and more specific than currently existing products. All of our prescription drug candidates are in either the pre-clinical or clinical trial stage
    PV-10
    Melanoma
      •    Prepare for Breakthrough Therapy Designation request 2013 into 2014
    •    Finalized Phase 2 data October 2012 and September 2013
    •    End-of-Phase 2 FDA meeting April 2010, March 2011, and October 2011
    •    Phase 2 study completed May 2010
    •    Phase 2 treatments completed September 2009
    •    Phase 2 recruitment completed May 2009
    •    Phase 2 study initiated September 2007
    •    Orphan drug status January 2007
    PH-10
    Psoriasis
      •    Toxicity study research and development for advanced studies 2012, 2013 and into 2014
    •    Phase 2c randomized study final data collection February 2012
    •    Phase 2c randomized study initiated December 2010 and completed August 2011
    •    Phase 2 study completed April 2010
    •    Phase 2 recruitment completed October 2009
    •    Replacement Phase 2 initiated July 2009 due to dose regimen change
    •    Phase 2 study initiated November 2007
    PH-10
    Atopic Dermatitis
      •    Toxicity study research and development for advanced studies 2012, 2013 and into 2014
    •    Phase 2 study completed September 2009
    •    Phase 2 recruitment completed June 2009
    •    Phase 2 study initiated June 2008
    PV-10
    Breast Cancer
      •    Assessing further development 2013 and 2014 in conjunction with Moffitt Cancer Center research
    •    Phase 1 study completed July 2008
    •    Phase 1 initial cohort treatment completed April 2006
    •    Phase 1 study initiated October 2005
    PV-10
    Liver Metasta

    Sentiment: Strong Buy

  • Reply to

    Has anyone google mapped their offices????

    by den1man Apr 9, 2014 2:47 PM
    yyyprionyyy yyyprionyyy Apr 10, 2014 7:59 AM Flag

    was apple and HP started in a garage smaller than Provectus?
    Yep...

  • yyyprionyyy yyyprionyyy Apr 10, 2014 7:57 AM Flag

    Are you the same plumber who claim to be a part time proctologist?

  • Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma.
    Ross MI.
    Author information
    Department of Surgical Oncology, Melanoma Section, M. D. Anderson Cancer Center, Houston, Texas.
    Abstract
    Rose Bengal is a novel injectable agent that has been evaluated as a rational treatment strategy for melanoma patients with recurrent unresectable local/regional metastases accessible for intralesional injection. PV-10 (10% Rose Bengal) has completed phase 1 and phase 2 multi-center clinical trials demonstrating significant local/regional disease control and also responses in non-injected regional bystander lesions and distant metastases. The published results of studies that have assessed PV-10 are presented, and the rationale for combining its use with recently approved immunotherapeutic agents is discussed.

  • yyyprionyyy yyyprionyyy Apr 4, 2014 3:06 PM Flag

    FDA approval even if BTD, will accelerate India pharma to get int he act to help the masses with low cost cure. China will too. The approval will be based on science and not hype. Agarwal, MD and Amod Sarnaik, MD will not spam the greatness of a simple drug Rose Bengal (PV-10) . They will not make a fool of themselves at the Poster Meeting . They have worked hard for what they have achieved. Google them for their credentials.. Patience will be rewarded.

  • How I Think About MannKind's Afrezza FDA Panel
    By: Adam Feuerstein | 01/10/14 - 11:37 AM EST

    Tweet CommentLink
    MannKind (MNKD) will bring its inhaled, rapid-acting insulin Afrezza in front of an FDA advisory panel on April 1. [Insert April Fool's Day jokes here.]

    In today's Biotech Stock Mailbag, I elaborated on my prediction that FDA would reject Afrezza. That was before the FDA panel announcement, so let's discuss further.

    -----------------
    FDA Panel Positive on MannKind's Afrezza
    Zacks By Zacks Equity Research
    21 hours ago

    Related Stories

    Positive CHMP Opinion for Novo Nordisk's Drugs Zacks
    MannKind Shares Rally 80% After FDA Group Recommends Afrezza Fox Business
    Repros Provides Proellex Update Zacks
    CHMP Backs Eli Lilly's Diabetes Drug Zacks
    Avanir's AVP-825 under FDA Review Zacks
    Good news flowed in at MannKind Corporation (MNKD) when the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (:FDA) voted in favor of the approval of the company’s diabetes candidate, Afrezza. We expect MannKind’s share price to appreciate significantly on the news.

  • MannKind MNKD +75.62% shares leapt 75%. The pharmaceutical company said late Tuesday its diabetes treatment Afrezza was recommended for approval by a Food and Drug Administration advisory committee. The FDA has until April 15 to make a decision.

    Sentiment: Hold

  • yyyprionyyy yyyprionyyy Apr 1, 2014 12:35 PM Flag

    or India for that matter. It is all about Medical Tourism. Big money. and cure for cancer.. With Obamacare in fullswing, reduced cost medical care with inexpensive medicine will get the nod faster... Lots of political pressure..

  • Can China make a pre emptive strike for approval of PV-10 before US FDA approval? What is the impact?

    Sentiment: Hold

  • Dr.Agarwal is cognizant of the fact for the potential cure of Breast Cancer without side effects. Support from the " Breast Cancer Cure Camp" will be significant.. My 2 cents worth..

    Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.

    Sentiment: Hold

  • yyyprionyyy yyyprionyyy Mar 31, 2014 3:53 PM Flag

    Will meet youguysta beach with My Prions that Multiply. if it reaches 10$ by April 16th... Meanwhile there will be daytraders pumping and dumping ... Just hold on and buy more at the dips..
    I still believe in the PV-10 logic, if there is reaction to PV-10 then there is 100% cure. If not try something else. It is the only drug that can be prescribed as an indicator, safely and applied to take advantage of bystander effect..

    Sentiment: Hold

  • if the logic says, PV-10 can be used an indicator for cure by injecting at the lesions with positive response, then injecting at 80% of the lesions will cure all of the lesions, with bystander effect.
    Do I make sense?

    Sentiment: Hold

  • why is PVCT going down 2.30 now

  • yyyprionyyy yyyprionyyy Mar 21, 2014 9:59 AM Flag

    if the logic says, PV-10 can be used an indicator for cure by injecting at the lesions with positive response, then injecting at 80% of the lesions will cure all of the lesions, with bystander effect.
    Do I make sense?

  • we neeed more shorts to provide Liquidity Jump right in at 7 please.
    Andy Marsh indirectly said that Andy Left is a LIar.. there will be Lawsuit agaist AndyLeft and Cramer for mental Anguish and suffering caused by them to PLUG and BLDP investors. lawyers Unite... This is your money maker.. LOL

  • Reading up on rose bengal. Australian Professor RIchard Kefford appeared in a 2008 video talking about the benefits of PV-10. I then googled Richard Kefford and l found this 2013 article:

    "An experimental drug with significant antitumour activity in advanced melanoma could be “the biggest thing in anticancer treatment in 30 years”, says a prominent Australian oncologist.

    "Professor Richard Kefford, Director of Sydney’s Westmead Institute for Cancer Research, is co-author of research presented at ASCO last week showing a 38% response rate for the immune checkpoint inhibitor lambrolizumab in a cohort of 135 advanced melanoma patients.
    The rate of confirmed improvement went up to 52% in those who had the highest doses of the drug and these responses were durable, with over 80% of patients still alive and on the drug at the time of publication.

    "Adverse effects were mild and mainly consisted of fatigue, rash, pruritus and diarrhoea, with only 13% of patients..."

    Then I found a 2013 article on the most promising cancer drugs. PV-10 was not among them. Nivolumab and Lambrolizumab were. Interestingly, Mr. Domingues, the Connecting the Dots blogger, in a recent entry in the "News" tab, compares these two drugs and others with PV-10 on a cost-basis. In the chart, PV-10, while being much cheaper, also has a much better CRR.

    I still shake my head in disbelief, even after months of being long PVCT, that a drug with superior data to any other melanoma drug, including combination therapies, is rarely mentioned in cancer treatment conversations. Dr. Kefford, five years later, is calling Lambrolizumab the biggest thing in anti-cancer treatment in 30 years. What does that say about PV-10, which has better data? Is it politics? It certainly can't be ignorance; the benefits of PV-10 have been known for years. But what the data shows in the Domingues chart apparently no one else sees, or if they do, they don't want to talk about it (YMB pumpers would have you believe big pharma knows; hence, the surge in combination therapy drugs). Nor do you see it in the New England Journal of Medicine, like Lambrolizumab. Why? What gives? Even if no one wants to see it, PV-10 has been around so long they can't miss it, if it is so revolutionary. Why the silence?

    Sentiment: Hold

  • BTD ... write up simple and FAST! I can write it for PVCT for faster approval.. They can reach me thru Yahoo boards.
    FDA stipulation " that the study "need not be large," "be adequate and well-controlled"
    4 out of 4 or 10 out of 10 will show that the if RB disoidum 10% solution causes pain after injection at melanoma lesions, the cure is guaranteed. The RB is an indicator as well as Curing agent. Two in One. What other medicine can do that.

    First use it as an Indicator agent if the cure with 10% RB is possible.

    If the response is blister, select those candidates and apply/inject more RB at every possible location. 100% success rate is guranteed. What other medicine can do this?
    FDA will buy this logis and approve in no time.
    The evidence is already there.
    Pure and simple..
    KG

    IF 10% RB does not blister and cause pain, there is no cure and no side effect. The Bystander effect is a Bonus for all patients.. What other miracle cure is there? to compare..
    ====
    No pumps or dumps DD based on your skillset..

    Sentiment: Hold

  • Reply to

    No Volume

    by stantonm35 Feb 6, 2014 12:06 PM
    yyyprionyyy yyyprionyyy Feb 6, 2014 4:07 PM Flag

    Put an order in for 20000 @1.80. got only 1700. looks like nobody wants to sell.. my order is still out here.. if you want to sell..

  • Reply to

    Anyone knows why price jump?

    by puts_or_calls Feb 3, 2014 10:41 AM
    yyyprionyyy yyyprionyyy Feb 3, 2014 12:24 PM Flag

    oversold.

PTX
4.70+0.38(+8.80%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.